TY - JOUR
T1 - Lipid Polymer Hybrid Nanomaterials for mRNA Delivery
AU - Zhao, Weiyu
AU - Zhang, Chengxiang
AU - Li, Bin
AU - Zhang, Xinfu
AU - Luo, Xiao
AU - Zeng, Chunxi
AU - Li, Wenqing
AU - Gao, Min
AU - Dong, Yizhou
N1 - Publisher Copyright:
© 2018, Biomedical Engineering Society.
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Introduction: In the past decade, messenger RNA (mRNA) has been extensively explored in a wide variety of biomedical applications. However, efficient delivery of mRNA is still one of the key challenges for its broad applications in the clinic. Recently, lipid polymer hybrid nanoparticles (LPNs) are evolving as a promising class of biomaterials for RNA delivery, which integrate the physicochemical properties of both lipids and polymers. We previously developed an N1,N3,N5-tris(2-aminoethyl)benzene-1,3,5-tricarboxamide (TT) derived lipid-like nanomaterial (TT3-LLN) which was capable of effectively delivering multiple types of mRNA. In order to further improve the delivery efficiency of TT3-LLN, in this study, we focused on studying the effects of incorporating different polymers on establishing LPNs and aimed to develop an optimized lipid polymer hybrid nanomaterial for efficient mRNA delivery. Methods: We incorporated a series of biodegradable and biocompatible polymer materials into the formulation of TT3-LLNs to develop LPNs. mRNA delivery efficiency of different LPNs were evaluated and a systematic orthogonal optimization was further carried out. Results: Our data indicated that PLGA4 (MW 24,000–38,000 g/mol) dramatically increased delivery efficiency of TT3-LLNs in comparison to other polymers. Further optimization identified PLGA4-7 LPNs (PLGA:mRNA = 9:1, mass ratio; TT3:DOPE:Cholesterol:DMG-PEG2000 = 25:25:45:0.75, molar ratio) as a lead formulation, which displayed significantly enhanced delivery of two types of mRNA in three different human cell lines as compared with TT3-LLNs. Conclusions: Results from this study potentially provide new insights into developing LPNs for mRNA based therapeutics.
AB - Introduction: In the past decade, messenger RNA (mRNA) has been extensively explored in a wide variety of biomedical applications. However, efficient delivery of mRNA is still one of the key challenges for its broad applications in the clinic. Recently, lipid polymer hybrid nanoparticles (LPNs) are evolving as a promising class of biomaterials for RNA delivery, which integrate the physicochemical properties of both lipids and polymers. We previously developed an N1,N3,N5-tris(2-aminoethyl)benzene-1,3,5-tricarboxamide (TT) derived lipid-like nanomaterial (TT3-LLN) which was capable of effectively delivering multiple types of mRNA. In order to further improve the delivery efficiency of TT3-LLN, in this study, we focused on studying the effects of incorporating different polymers on establishing LPNs and aimed to develop an optimized lipid polymer hybrid nanomaterial for efficient mRNA delivery. Methods: We incorporated a series of biodegradable and biocompatible polymer materials into the formulation of TT3-LLNs to develop LPNs. mRNA delivery efficiency of different LPNs were evaluated and a systematic orthogonal optimization was further carried out. Results: Our data indicated that PLGA4 (MW 24,000–38,000 g/mol) dramatically increased delivery efficiency of TT3-LLNs in comparison to other polymers. Further optimization identified PLGA4-7 LPNs (PLGA:mRNA = 9:1, mass ratio; TT3:DOPE:Cholesterol:DMG-PEG2000 = 25:25:45:0.75, molar ratio) as a lead formulation, which displayed significantly enhanced delivery of two types of mRNA in three different human cell lines as compared with TT3-LLNs. Conclusions: Results from this study potentially provide new insights into developing LPNs for mRNA based therapeutics.
KW - Lipid polymer hybrid nanoparticles (LPNs)
KW - Lipids
KW - mRNA therapeutics
KW - Orthogonal experiment design
KW - Poly (lactic-co-glycolic acid) or PLGA
KW - Polymers
UR - http://www.scopus.com/inward/record.url?scp=85048827832&partnerID=8YFLogxK
U2 - 10.1007/s12195-018-0536-9
DO - 10.1007/s12195-018-0536-9
M3 - Article
AN - SCOPUS:85048827832
SN - 1865-5025
VL - 11
SP - 397
EP - 406
JO - Cellular and Molecular Bioengineering
JF - Cellular and Molecular Bioengineering
IS - 5
ER -